AstraZeneca Educational Webinar Series

Presented by AADE in Association with AstraZeneca-US Medical Affairs, CVMD Division

This educational webinar series is designed to provide the most up-to-date, cutting edge information in diabetes. Each webinar will be presented live and recorded. Archived presentations will be posted on this page for up to 40 days after the live broadcast, so don't miss out!

This webinar series is educational in nature and contains no promotional or product information. CE credit is not available for this activity.






Webinar Schedule:

June 6: GLP-1 Physiology and Overview of Approved GLP-1 Receptor Agonists

July 11: Use of Sodium Glucose Co-Transporter Inhibitors (SGLT-2is) to Treat Adults with Type 2 Diabetes

September 12: Combination Therapy

October 17: Cardiovascular/Metabolic Disease




GLP-1 Physiology and Overview of Approved GLP-1 Receptor Agonists


Presented by James Ruggles, PhD, and Curtis Triplitt, PharmD, CDE, this webinar will review the key hormones for glucose homeostasis and then focus on the incretin hormone GLP-1. The actions of GLP-1 will be covered in both normal physiology and the pathophysiology of type 2 diabetes. Finally, there will be an overview of key clinical and safety data of approved GLP-1 receptor agonists.

Upon completion of this activity, participants will be able to:

  1. Provide an overall understanding of the glucose-dependent actions of GLP-1 and how GLP-1 receptor agonists share these actions.
  2. Educate on intermittent and long-acting GLP-1 receptor agonists and how these agents differ in actions.
  3. Provide an overview of key clinical and safety data for the class.

Originally presented on June 6, 2018





Coming Soon: Use of Sodium Glucose Co-Transporter Inhibitors (SGLT-2is) to Treat Adults with Type 2 Diabetes

Presented by Like Jiang, MD, and Curtis Triplitt, PharmD, CDE, this webinar will review the role of the kidneys for glucose homeostasis. The mechanism of action for SGLT-2 inhibitors will be covered, as well as an overview of the SGLT-2 inhibitors currently available in the US. Finally, there will be an overview of the SGLT-2is Cardiovascular Outcome Trials (CVOTs).

Upon completion of this activity, participants will be able to:

  1. Describe the mechanism of action for SGLT-2 inhibitors.
  2. Educate on the role of the kidneys for glucose homeostasis.
  3. Provide an overview of SGLT-2i CVOTs.